Formulation, Analytics, and Translational Execution
Dharma Biologics | Bengaluru, India
Development is where manufacturing reality is either anticipated or ignored. Many programs fail later not because development was incomplete, but because it was disconnected from how products would ultimately be manufactured, tested, transferred, and regulated. Data is generated, but insight is not. Methods are developed, but not stress-tested. Formulations are selected, but not challenged against scale or delivery constraints.
Dharma Biologics operates Development & Science as the intellectual backbone of our CDMO. We are not a laboratory that hands work downstream; we are a development organization whose purpose is to make manufacturing inevitable rather than uncertain.
As a biopharmaceutical development CDMO in India, our development philosophy is simple: every experiment must reduce future risk, not just advance the program on paper.
Development as a Translational Discipline
True development is translational. It connects molecule to process, process to analytics, analytics to regulation, and regulation to commercial execution. When any of these links are weak, problems surface later under conditions where they are expensive, visible, and difficult to fix.
At Dharma Biologics, Development & Science is structured to answer downstream questions early. We ask how a formulation will behave under shear, how an impurity profile will evolve at scale, how an analytical method will perform during validation, and how regulators will interrogate the data. This mindset differentiates a capable lab from a serious development CDMO in India.
Formulation Science: Designing for Manufacturability
Formulation science is often treated as a search for stability. In practice, it is a search for tolerance. A formulation that is stable only under ideal conditions is not manufacturable. Dharma Biologics designs formulations that tolerate realistic variability in temperature, time, mechanical stress, and materials.
We evaluate excipient function not only in terms of stabilization, but also in how excipients influence viscosity, syringeability, filtration behavior, and long-term interaction with containers and devices. Buffer systems are selected with attention to pH drift and ionic strength effects. Where tradeoffs are unavoidable, they are documented transparently so sponsors understand the limits of the system.
Our formulation development capabilities include:
- Liquid and lyophilized formulation development
- High-concentration and viscosity-sensitive formulations
- Long-acting and controlled-release systems
- Suspension and microsuspension injectables
- Formulation screening under mechanical and thermal stress
Analytical Development as Infrastructure
Analytics are not a reporting function; they are infrastructure. Without robust analytical methods, process understanding remains superficial and regulatory defensibility weak. Dharma Biologics integrates analytical development tightly with formulation and process work so that methods evolve alongside the product.
We develop analytical methods to be stability-indicating, transferable, and validation-ready. Methods are challenged deliberately to understand sensitivity, specificity, and robustness. This approach prevents the common failure mode where methods pass development only to collapse during validation or inspection.
Analytical development capabilities include:
- Identity, purity, and impurity profiling
- Potency and functional assays
- Particle and aggregation analysis
- Residuals and trace impurity methods
- Stability-indicating method development
Method Validation with Intent
Validation is often treated as a procedural exercise. At Dharma Biologics, method validation is used to confirm that analytical tools can withstand real-world use. We design validation protocols that reflect routine operating conditions rather than idealized laboratory scenarios.
Acceptance criteria are justified scientifically. System suitability is meaningful. Data integrity is embedded into workflows rather than layered on after the fact. This discipline is essential for any development CDMO in India supporting late-stage or global programs.
Stability Studies: Understanding Change Over Time
Stability is not a single endpoint; it is a trajectory. Dharma Biologics designs stability programs to reveal how products change, not merely whether they remain within specification. We examine degradation pathways, interaction effects, and variability across batches to understand long-term behavior.
Stability data is used actively to refine formulation, packaging, and process parameters. Emerging trends are investigated early, when mitigation is still feasible. This proactive approach reduces surprises during clinical progression or commercialization.
Extractables, Leachables, and Material Interaction Studies
Material interactions are a recurring source of late-stage risk. Dharma Biologics integrates extractables and leachables studies into development rather than treating them as isolated regulatory requirements. We assess material compatibility in the context of formulation chemistry, storage conditions, and delivery systems.
This integrated approach allows potential risks to be identified and mitigated early, avoiding disruptive changes later in development.
Comparability and Bridging Science
Changes are inevitable in development. What matters is whether changes are understood and justified. Dharma Biologics supports comparability and bridging studies designed to demonstrate that changes do not alter critical quality attributes.
We structure comparability programs to align with regulatory expectations, using analytical depth and statistical rigor appropriate to the risk profile of the change. This capability is particularly important for sponsors navigating scale-up, site transfer, or post-approval modification.
Process Development Integration
Development at Dharma Biologics does not occur in isolation from manufacturing. Process development teams work alongside formulation and analytical scientists to ensure that decisions are grounded in execution reality.
We evaluate how development choices influence mixing behavior, heat transfer, filtration performance, and purification efficiency. Development data is captured in a form that supports scale-up and tech transfer, reducing friction downstream.
Regulatory Science and Documentation
Regulators expect development narratives that demonstrate understanding, not just compliance. Dharma Biologics builds regulatory science into development activities so that documentation reflects causality rather than chronology.
We support sponsors by generating development reports that explain why decisions were made, how risks were assessed, and how controls were established. This narrative clarity is a defining characteristic of a mature biopharmaceutical development CDMO in India.
Supporting Innovation Without Fragility
Emerging modalities and novel formulations often expose gaps in legacy development approaches. Dharma Biologics supports innovation by adapting scientific rigor to new contexts rather than forcing novel products into outdated frameworks.
Whether supporting early-stage innovation or late-stage optimization, our Development & Science function is designed to stabilize programs, not accelerate them recklessly.
Closing Perspective
Strong development does not eliminate risk; it makes risk visible and manageable. Dharma Biologics operates Development & Science as a discipline of anticipation, ensuring that manufacturing, regulatory, and commercial realities are addressed early and honestly.
From Bengaluru, and across our integrated CDMO Network, we provide development capabilities that transform uncertainty into executable systems.
ವಿಕಾಸದಲ್ಲಿ ವಿವೇಕ. ವಿಜ್ಞಾನದಲ್ಲಿ ದೃಢತೆ.
Email our team at info@dharmabiologics.com